CJC-1295 (Mod GRF 1-29)
Updated: Apr 7, 2022
A Growth Hormone Increasing Peptide
Subcutaneous injection. 100mcg dose 1-3 times per day.
Anti-aging purposes: 100mcg of Modified GRF 1-29 once daily before bed on empty stomach.
Recovery: 100mcg administered 3 times a day in combination with a GHRP.
Stimulates the natural release of growth hormone
Promotes calcium retention and increases bone density
Promotes increased protein synthesis and muscle growth while strengthening the cardiovascular system
Promotes the breakdown of fats
Treats muscle disorders and burns
Increased sexual drive
Decreases recovery times
Strengthens immune system
Improves cognitive and memory function
Improves insulin sensitivity and reduces high blood sugars
Buy CJC-1295 (modified GRF 1-29) from Canada here.
Buy CJC-1295 (modified GRF 1-29) from USA here.
CJC-1295 without DAC or Modified GRF 1-29 is a growth hormone secretagogue compound which stimulates increased secretion of growth hormone from the pituitary gland. It acts as a peptide analogue of growth hormone releasing hormone (GHRH). GHRH is the chemical produced by the body that stimulates natural growth hormone production. It was developed in early 1980s and subsequent research has found CJC-1295 to accelerate muscle repair and growth, wound healing, bone developement and strengthening, improve immune function and more. It has been used in research to stimulate the body's natural growth hormone production. By enhancing growth hormone production, the subject reaps the benefits of higher HGH, including muscle repair, muscle growth, increased lean body mass, decreased body fat, enhanced wound healing and recovery, improved sleep, better joint health and improved immune function. Mod GRF 1-29 has also been associated with increased IGF-1 (Insulin-like Growth Factor) which stimulates improvements in body composition.
Is CJC-1295 Mod GRF 1-29 Suppressive?
No negative side-effects have been assoicated with CJC-1295. Mod GRF 1-29 stimulates the body's natural production of HGH and thus avoids shutting down natural growth hormone production unlike synthetic HGH. No synthetic side-effects, including carpal tunnel or acromegaly, have been documented with Mod GRF 1-29
How does it work?
Mod GRF 1-29 binds to GHRH receptors in the pituitary gland where increases the pulsative releases of growth hormone and consequently increasing IGF-1 production.
Mod GRF 1-29 works best when administered at the same time as the natural release of growth hormone in the body which can either be timed or administered in conjunction with a GHRP peptide.
Side-effects: Upon initial administration, some symptoms may occur, such as: mild skin flushing, nausea, stomach upset, dizziness, and/or headache. These reactions tend to dissipate after repeated injections. Feelings of tiredness or lethargy are possible as well, as growth hormone can increase the desire for sleep as well as its quality and restorative capabilities.
Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman, Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults, The Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 3, 1 March 2006, Pages 799–805, https://doi.org/10.1210/jc.2005-1536
Context: Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.
Objective: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog.
Design: The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.
Setting: The study was performed at two investigational sites.
Participants: Healthy subjects, ages 21–61 yr, were studied.
Interventions: CJC-1295 or placebo was administered sc in one of four ascending single doses in the first study and in two or three weekly or biweekly doses in the second study.
Main Outcome Measures: The main outcome measures were peak concentrations and area under the curve of GH and IGF-I; standard pharmacokinetic parameters were used for CJC-1295.
Results: After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9–11 d. The estimated half-life of CJC-1295 was 5.8–8.1 d. After multiple CJC-1295 doses, mean IGF-I levels remained above baseline for up to 28 d. No serious adverse reactions were reported.
Conclusions: Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.
R. Valcavi et al studied the effect of GRF 1-29 in patients with hypothyroidism, where the thyroid does not create or release enough thyroid hormones into the blood stream, negatively impacting the metabolism. Hypothyroidism has been assoicated with impaired GH responses. They studied the peak GH responses to GRF 1-29 with and without administration of T4. They found T4 hormone significantly increases the GH response to GRF 1-29 in patients with hypothyroidism.
All information found on vantanexcorp.com, and its associated blog is intended for informational and entertainment use only. Vantanex Corp does not provide medical advice. Vantanex Corp tries to provide the most recent and up-to-date research however can make no guarantees this is the case. Vantanex Corp does not condone the use of illegal drugs or the use of drugs for unintended purposes. Before taking any medication, over-the-counter drugs or medication, seek medical advice from a medical professional. No liability will be assumed for the use of these articles, the contained information is not medical advice.
For more information on the buying Terms & Conditions from Vantanex Corp, click here.